Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis

Journal of Nuclear Cardiology

Volumn 26, Issue 5, 2019, Pages 1630-1637

  Sperry, Brett W ^a,b   Gonzalez, Matthew H ^a   Brunken, Richard ^a   Cerqueira, Manuel D ^a   Hanna, Mazen ^a   Jaber, Wael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

advanced cardiac imaging; heart failure with preserved ejection fraction; Infiltrative cardiomyopathies; nuclear cardiac imaging

Indexed keywords

PYROPHOSPHATE TECHNETIUM TC 99M; TRANSTHYRETIN; DIPHOSPHORIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; TECHNETIUM;

AGED; ARTICLE; BICEPS BRACHII MUSCLE; BONE; CARDIAC MUSCLE; DRUG UPTAKE; FEMALE; GENETIC DISORDER; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSOAS MUSCLE; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SKELETAL MUSCLE; X-RAY COMPUTED TOMOGRAPHY; BIOPSY; DIAGNOSTIC IMAGING; FAMILIAL AMYLOID POLYNEUROPATHY; METABOLISM; MIDDLE AGED; VERY ELDERLY; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; BIOPSY; DIPHOSPHATES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 85040646261     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-017-1166-7     Document Type: Article

References (11)

1. Dorbala S, Bokhari S, Miller EJ, Bullock-Palmer R, Soman P, Thompson R (2017) 99mTechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis. ASNC Pract. Points.
2. Vranian MN, Sperry BW, Hanna M et al (2017) Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes. J Nucl Cardiol Off Publ Am. Soc Nucl Cardiol. 10.1007/s12350-016-0768-9.
3. Hutt DF, Quigley A-M, Page J et al (2014) Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 15:1289-1298.
4. Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404-2412.
5. Sperry BW, Vranian MN, Hachamovitch R et al (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214:477-481.
6. Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076-1084.
7. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6:195-201.
8. DiCola VC, Freedman GS, Downing SE, Zaret BL (1976) Myocardial uptake of technetium-99m stannous pyrophosphate following direct current transthoracic countershock. Circulation 54:980-986.
9. Sueyoshi T, Ueda M, Jono H et al (2011) Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol 42:1259-1264.
10. Quarta CC, Gonzalez-Lopez E, Gilbertson JA et al (2017) Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 10.1093/eurheartj/ehx047.
11. Castano A, Haq M, Narotsky DL et al (2016) Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol1:880-889.